2024-10-17 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis: 

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and markets a wide range of medicines, including immunology, oncology, neurology, and eye care products.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** ABBV has outperformed the S&P 500 (VOO) with a cumulative return of 149.37% compared to VOO's 135.94%. 
* **Relative Outperformance:** ABBV has outperformed the S&P 500 by 13.43 percentage points. This translates to a relative outperformance ranking of 55.19% (indicating it's outperformed the S&P 500 in 55.19% of historical periods).

**2. Recent Price Movement:**

* **Current Price:** $191.86
* **5-Day Moving Average:** $194.04
* **20-Day Moving Average:** $194.21
* **60-Day Moving Average:** $192.42

The current price is below the 5-day and 20-day moving averages, suggesting a possible short-term downtrend. However, the price is still above the 60-day moving average, indicating a potential for long-term upward momentum.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 51.57
* **PPO (Percentage Price Oscillator):** -0.17
* **Delta_Previous_Relative_Divergence:** -7.98 (Negative, indicating a short-term downtrend)
* **Expected_Return:** 1.76% (Potential 5-year expected return over the S&P 500)

The RSI indicates neutral momentum, while the negative PPO suggests a slight downtrend. The negative Delta_Previous_Relative_Divergence further reinforces the short-term downtrend. 

**4. Recent Earnings:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

ABBV has consistently exceeded earnings estimates in recent quarters. The most recent quarter (2024-07-25) saw EPS of 2.65, beating expectations of 2.57. This suggests continued strong performance and potentially positive market sentiment.

**5. News and Recent Issues:**

* **Recent Market Outlook:** AbbVie has received a "Hold" rating from most analysts, with a price target of around $195. The stock has been impacted by some concerns regarding its Humira biosimilar competition and the potential for future revenue declines. 
* **Analyst Opinions:** While some analysts remain optimistic about AbbVie's long-term growth prospects, driven by its robust pipeline and ongoing diversification efforts, others are more cautious due to the competitive landscape. 
* **Performance Highlights:** ABBV continues to be a profitable company with strong market share in several key therapeutic areas. Its recent earnings beat reflects the company's continued ability to deliver on its financial targets despite the competitive pressures.

**6. Overall Analysis:**

ABBV has exhibited solid performance, consistently exceeding earnings expectations and outperforming the S&P 500. However, current technical indicators and some market concerns regarding competition suggest a potential short-term downtrend. Long-term prospects remain positive due to ABBV's strong pipeline and ongoing diversification efforts.

**7. Summary:**

ABBV has a long history of strong performance and continues to be a profitable company. The recent earnings beat is a positive sign, but short-term price action suggests potential for a downtrend. While the stock has outperformed the market in the past, potential competition and some market concerns remain. Investors should monitor ABBV closely and consider the long-term growth potential alongside any short-term fluctuations. 
